In this issue:
Genetically adjusted PSA levels for prostate cancer screening
Radium-223 in mCRPC
Response to new hormonal agents in mHSPC
Darolutamide + ADT and docetaxel in mHSPC
Darolutamide maintenance in mCRPC with nonprogressive disease after taxane
Post-diagnostic health behaviour and prostate cancer progression and mortality
Standardised prostate cancer incidence and mortality rates after initial non-malignant biopsy
ADT and radiotherapy with or without docetaxel for localised high-risk prostate cancer
Prognostic estimation incorporating imaging- vs digital rectal-based staging
Second-line therapies for metastatic neuroendocrine prostate cancer
Please login below to download this issue (PDF)